TRACE4AD

DeepTrace Technologies Srl

TRACE4AD provides the subject's level of risk (low or high risk) of having or progressing to Alzheimer's disease dementia within 24 months, by an automatic reading of the subject's brain gray matter obtained from a 3D structural T1-weighted MRI brain study, also in combination with subject’s neuropsychological measures.
Product specifications Information source: Vendor
Last updated: April 19, 2022
General
Product name TRACE4AD
Company DeepTrace Technologies Srl
Subspeciality Neuro
Modality MR
Disease targeted Alzheimer’s disease dementia
Key-features Mild cognitive impairment (MCI) subject risk score (low risk vs high risk) of being affected by or progressing to Alzheimer's disease dementia within 24 months, cognitive, functional and behavioral deficits of the subject, subject gray matter volume and images with normative comparison, best voxel-based map predictors overlayed on the subject gray matter, best neuropsychological predictors
Suggested use During: interactive decision support (shows abnormalities/results only on demand), report suggestion
After: diagnosis verification
Data characteristics
Population Amnestic Mild Cognitive Impairment (MCI) subjects on the recommendation of neurology specialists
Input T1-weighted, MP-RAGE, 3D MRI; brain, cognitive, functional and behavioral measures
Input format DICOM, Nifti, nrrd, pdf
Output High vs low risk of being affected by or progressing to AD dementia within 2 years, cognitive functional and behavioral deficits, gray matter volume and images, voxel-based map predictors overlayed on gray matter, best neuropsychological predictors
Output format pdf
Technology
Integration Stand-alone third party application, Stand-alone webbased
Deployment Locally on dedicated hardware, Cloud-based
Trigger for analysis On demand, triggered by a user through e.g. a button click, image upload, etc.
Processing time > 10 minutes
Certification
CE
Certified, Class I , MDD
FDA
 No or not yet
Market presence
On market since 05-2021
Distribution channels
Countries present (clinical, non-research use)
Paying clinical customers (institutes)
Research/test users (institutes)
Pricing
Pricing model Subscription
Based on Number of users, Number of installations, Number of analyses
Evidence
Peer reviewed papers on performance

  • TRACE4AD v2.0: MRI characterizes the progressive course of AD and predicts conversion to Alzheimer’s dementia 24 months before probable diagnosis (read)
Non-peer reviewed papers on performance
Other relevant papers